ClinicalTrials.gg

Program

irpagratinib

Also written as “ABSK-011 Capsules”, “ABSK-011” and “ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w”.

Its studies are mostly in Carcinoma, Hepatocellular · Liver Neoplasms, led by Abbisko Cayman.

Furthest: phase 2, since Jun 28, 20226 company-led studies, 5 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbisko Cayman65 open or runningphase 2since Jun 28, 2022Apr 21, 2021Jun 30, 2027phase 2 · NCT07327034

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2021First study: phase 1 study in Advanced Liver CancerFirst studyNCT04906434 · 200 planned · United States, China, Taiwan
  2. Jun 28, 2022Phase 2 study in Carcinoma, HepatocellularNCT05441475 · 118 planned · China
  3. Feb 6, 2024Phase 1 study in Healthy SubjectsNCT06306872 · 40 enrolled · China
  4. Mar 20, 2025Phase 1 study in Healthy SubjectsNCT06896760 · 6 planned · China
  5. Nov 26, 2025Phase 2 study in Carcinoma, HepatocellularNCT07327034 · 141 planned · China
  6. Jul 8, 2026Phase 1 study in Healthy ParticipantsNCT07700953 · 30 planned · China

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07327034
  2. Dec 31, 2027Primary completion: phase 1 study in Advanced Liver CancerNCT04906434
  3. Dec 31, 2028Primary completion: phase 2 study in Carcinoma, HepatocellularNCT05441475

TargetBeta

FGFR4 →read by rule
“An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), ”NCIt, by rule

Other programs on FGFR4

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
infigratinibruleBridgeBiophase 317
futibatinibruleOtsukaphase 310
BB102rulebroadenbio-ltd-cophase 22

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07700953Healthy Participants · China1RecruitingAug 10, 202630
NCT07327034Carcinoma, Hepatocellular · China2RecruitingJun 30, 2027141
NCT06896760Healthy Subjects · China1Not yet recruitingNov 7, 20256
NCT06306872Healthy Subjects · China1CompletedSep 30, 202540
NCT05441475Carcinoma, Hepatocellular · China2By invitationDec 31, 2028118
NCT04906434Advanced Liver Cancer · United States, China, Taiwan1RecruitingDec 31, 2027200

How it is read

Names in the registry

  • “ABSK-011 Capsules”, 1 entry
  • “ABSK-011”, 1 entry
  • “ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w”, 1 entry
  • “ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg”, 1 entry
  • “ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg”, 1 entry

Codes read as this program: ABSK011.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.